Dianalitics
Annovis Bio, Inc.
ANVS · v1 · 2026-09-23
arrow_back
homeHomemonitoringPerformancesearch
hourglass
Loading…
Preparing the latest DD data, styles and content.
46NeutralDD: Sep 23, 2026Analyst: 44
paidPrice at analysis date
USD 1.26 (23/09/2026)
domainMkt cap
$54M
pie_chartShares
42.6M
candlestick_chart52W
$1.04-$5.50
trending_downShort interest
11.7%
HIGHNYSEHealth Care15 employeesFounded 2008
Verdict: Speculative — Binary bet on Phase 3 buntanetap Q1 2027 readout

Nano-cap (~$54M) with lead asset buntanetap in a fully-enrolled 850-patient pivotal Phase 3 Alzheimer's trial (6-month primary readout Q1 2027, 18-month disease-modifying readout Q1 2028). Cash runway just ~5 months (~$18.7M vs $43M annual burn) — capital raise imminent and dilutive. Prior Phase 2/3 data has been controversial, with historical class actions and shareholder investigations weighing on credibility. Pure lottery-ticket asymmetry: base FV $2.50 (+98% from $1.26), but −75% downside on Phase 3 miss and >100% dilution risk in interim. Only appropriate for size-adjusted binary biotech exposure.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-09-23
44
Annovis Bio, Inc. (ANVS)
Clinical Neurodegenerative · NYSE · Malvern, PA
"Fully-enrolled Phase 3 with imminent binary readout, but 5-month runway + heavy dilution risk = binary bet."
P3 fully enrolled 5-mo runway Dilution imminent Q1 2027 readout Patent to 2047
Fin. strength
3
/20 pts
EBITDA/FCF
1
/15 pts
Debt/leverage
10
/15 pts
Stage/business
8
/15 pts
Catalysts
9
/10 pts
Reg. risk
3
/8 pts
Risk/reward
5
/7 pts
Management
2
/5 pts
Sector/macro
2
/3 pts
Compliance
1
/2 pts
💡 Fair Value Estimate — rNPV on buntanetap Alzheimer's + dilution adjustment
Fair value base case
USD 2.50
Range: USD 0.30-USD 12.0
Price at analysis date: USD 1.26 (23/09/2026)
Base upside/downside: +98%

Risk-adjusted NPV sum-of-parts on Phase 3 buntanetap. PoS 10% assumes CNS Phase 3 base rate — buntanetap's prior Phase 2/3 data was mixed (positive biomarker signals but disputed cognitive endpoint interpretation), justifying below-mean assumption. $2B peak sales assumes ~5-8% share of AD replacement market ($30B+ TAM). Dilution modeled explicitly at $60M/$1.50 = 94% share increase. Cross-check via option premium interpretation: current $54M mcap ≈ 6% implied probability × $900M expected value. Base FV $2.50 differs 76% from analyst consensus $10.50 because consensus typically excludes explicit dilution modeling. Bear-heavy probability weighting (45%) reflects Phase 3 CNS base rate. ⚠️ Not investment advice.

ComponentAssumptionUSD/share
Buntanetap AD (Phase 3 rNPV)$2.0B peak × 10% PoS × 2.0x NPV multiple = $400M / 42.6M shares+9.39
Buntanetap PD (Parkinson's option)$600M peak × 6% PoS × 1.5x = $54M / 42.6M shares+1.27
PD dementia optionality15% probability × $80M NPV / 42.6M shares+0.28
Net cash$18.7M cash − $0 debt = $18.7M / 42.6M+0.44
Expected dilution$60M raise at $1.50 avg = +40M shares (94% dilution); FV rebased on 82.6M shares−5.85
Litigation/governance reserveHistorical class actions + governance discount; $8M reserve / 82.6M shares−0.10
Execution/timing haircut30% discount to sum for Phase 3 timeline slippage and readout tail risk−2.93
FV base caseArithmetic sum: +9.39 +1.27 +0.28 +0.44 −5.85 −0.10 −2.93 ≈ $2.50≈ $2.50
Bull
$8 – $12
Probability: 15%
Phase 3 AD primary endpoint hit at Q1 2027 with statistically significant cognitive benefit; partnership or acquisition deal at premium; dilutive raise avoided or delayed. FV re-rates to $8-12 based on de-risked NPV. Return +530-850%.
Base
$1.50 – $3.50
Probability: 40%
Mixed Phase 3 outcome or ambiguous data; dilutive $50-80M raise executed at $1.50 average; secondary readout at Q1 2028 becomes new key event. Return +20-180%.
Bear
$0.30 – $0.80
Probability: 45%
Phase 3 primary endpoint miss OR pre-readout raise at $0.75-1.00/sh forced by cash depletion; NYSE listing risk if price drops below $1 for 30+ days. Total return −40% to −80%.
Methodology: Risk-adjusted NPV sum-of-parts on Phase 3 buntanetap. PoS 10% assumes CNS Phase 3 base rate — buntanetap's prior Phase 2/3 data was mixed (positive biomarker signals but disputed cognitive endpoint interpretation), justifying below-mean assumption. $2B peak sales assumes ~5-8% share of AD replacement market ($30B+ TAM). Dilution modeled explicitly at $60M/$1.50 = 94% share increase. Cross-check via option premium interpretation: current $54M mcap ≈ 6% implied probability × $900M expected value. Base FV $2.50 differs 76% from analyst consensus $10.50 because consensus typically excludes explicit dilution modeling. Bear-heavy probability weighting (45%) reflects Phase 3 CNS base rate. ⚠️ Not investment advice. Not investment advice.
warning
🚨 Cash runway ~5 months · Imminent raise almost certain · Nano-cap volatility
$18.7M cash at Q2 2026 vs annualized ~$43M burn = runway to early Q1 2027. Company must raise before or immediately after the Phase 3 primary readout. Any pre-readout raise at current $1.26 requires issuing 40-80M new shares (equivalent to 100-190% dilution of existing 42.6M share base). Post-raise share count likely 85-125M — must be modeled explicitly in any per-share fair value. Negative tangible book value −$4.25M signals accumulated losses have consumed all paid-in equity.
check_circle
✅ Fully-enrolled Phase 3 Alzheimer's trial with dated primary readout Q1 2027
850 patients enrolled across 83 US sites in July 2026 (exceeding original targets). Randomized, double-blind, placebo-controlled design in early Alzheimer's disease (MMSE 20-28, pTau217-biomarker-positive). 6-month symptomatic data expected Q1 2027 with ADAS-Cog13 primary cognitive endpoint. DSMB (Data Safety Monitoring Board) already cleared safety at 6 months. Patent protection on crystal form extends to 2047.
⚠️ Methodology note: ANVS is a nano-cap (below $300M) clinical-stage biotech with essentially no revenue and a single primary asset. Fair value derived from risk-adjusted NPV (rNPV) on buntanetap AD program, adjusted for near-certain dilution from upcoming capital raise. Sensitivity to Phase 3 outcome is extreme — this is inherently a binary bet, not a fundamental compounder.
📊 Capital Structure · Short Interest · Buyback & Dilution
🟡 Short Interest
11.7%
~5.0M shares short on 42.6M outstanding. Days to cover ~2.8. Elevated for nano-cap; positive Phase 3 readout could trigger sharp short squeeze given tiny float. Borrow rate likely elevated.
🔴 Share dilution (1Y)
+45%
From ~29M to ~42.6M shares over 12 months. Cause: multiple ATM offerings and registered direct raises. Additional dilution 40-80M shares likely within 3-6 months.
🔴 Buyback
$0
No repurchase program. All resources devoted to Phase 3 trial completion and readout preparation. Buyback impossible until commercial cash flow.
Short Interest — context
ANVS — 11.7%
11.7%

At 11.7% short interest with a ~42.6M share float, ANVS carries meaningful squeeze potential on positive clinical print. Historically the stock has seen 3-5x intraday moves on data announcements (2021 P2 data +200%, 2024 P3 update −40%). Historical class actions (2021 Robbins, 2024 Glancy Prongay & Murray investigations) documented in public filings but no current active case identified in trailing 12 months. Insider transactions per SEC Form 4 filings show routine option/RSU activity, no material sales.

$Financial analysis — FY2026E
Cash (Q2 2026)
$18.7M
Runway ~5 months at $43M annual burn
TTM Net loss
−$49.5M
EPS −$1.79; consistent with Phase 3 spending
TTM FCF
−$43.3M
Peak spend period for Phase 3
Tangible book
−$4.3M
Negative equity — accumulated deficit exceeds paid-in capital
Item ($M)FY2023FY2024FY2025FY2026EGuidance FY2027E
Revenue00000 (pre-launch)
R&D expense25.420.025.2~3815–25 (post-readout)
G&A expense7.16.74.5~5.55–7
Net loss−32.5−26.7−29.7~−49−20 to −35
Cash & equivalents (EOP)18.410.619.5~5-10 (pre-raise)Requires ≥$60M raise
Shares outstanding (M)9.913.629.4~42.685–125 (post-raise)
Note: FY26E reflects peak Phase 3 execution spending. Guidance FY27E assumes post-primary-readout normalized spend. Historical from 10-K filings.
Quarterly dynamics — last 5 quarters
MetricQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Revenue ($M)00000
R&D expense ($M)6.57.26.89.410.1
Net loss ($M)−8.1−8.9−8.3−17.6−14.7
End-of-period cash ($M)14.513.119.526.518.7
Financial position and sustainability
Cash runway (months)
~5
Phase 3 AD enrollment
100%
Dilution vs 2Y ago
+330%
account_tree

Business model — Single-asset CNS binary bet

Buntanetap: translational inhibitor targeting neurodegenerative disease
Annovis' entire equity value rests on buntanetap (posiphen), an oral small-molecule translational inhibitor designed to reduce production of multiple neurotoxic proteins (APP/amyloid, tau, α-synuclein, TDP-43) simultaneously. This "one drug, multiple targets" hypothesis differentiates from single-target agents like Leqembi (anti-amyloid antibody). Pipeline: (1) buntanetap for early Alzheimer's (Phase 3, fully enrolled), (2) buntanetap for Parkinson's Disease (open-label extension study started Jan 2026), (3) buntanetap for Parkinson's Disease Dementia (FDA-endorsed program). Company essentially a one-drug story with three indication tracks; approval in any single indication would validate the mechanism.

Buntanetap AD (Phase 3) Peak $2-4B TAM 🟡 P3 fully enrolled 850 patients, 83 US sites, pTau217-positive early AD (MMSE 20-28). DSMB safety clear at 6 months. Primary endpoint ADAS-Cog13 cognitive change. Q1 2027 readout = thesis-defining event. Buntanetap PD (Extension) Peak $500M-1B TAM 🟡 open-label extension OLE started Jan 2026 with biomarker data showing cognitive improvement in impaired PD patients and reduced amyloid/tau pathology. FDA endorsed proceeding with a PD Dementia study. Buntanetap PDD program Optionality 🟢 FDA-endorsed Parkinson's Disease Dementia represents an underserved market where buntanetap's multi-target mechanism could differentiate. Trial design and initiation still to be finalized; funding-dependent.

gavel

Legal, regulatory and risk analysis

Cash runway crisis
Critical
$18.7M cash vs ~$3.6M monthly burn = 5-month runway. Must raise capital before Q1 2027 Phase 3 readout OR complete a pre-financing to bridge readout. Timing and pricing of this raise is arguably more important than Phase 3 outcome for near-term equity value.
Phase 3 primary endpoint miss risk
High
Base rate for CNS Phase 3 trials is 8-15% success. Buntanetap's prior Phase 2/3 data was mixed — positive biomarker signals but disputed cognitive endpoint interpretation drew scrutiny. Q1 2027 primary readout could produce −70-90% single-day equity decline on miss.
Massive dilution (40-80M new shares)
High
$60M raise at $1.50 = 40M shares (94% dilution). $100M raise at $0.75 (post-miss scenario) = 133M shares (312% dilution). Existing 42.6M holders will be substantially diluted regardless of scenario. Fair value per share must be modeled on post-raise share count.
NYSE listing compliance risk
Moderate
$1.26 current price sits ~26% above NYSE $1.00 minimum bid requirement. A 30-day close below $1.00 would trigger a listing deficiency notice with 6-month cure period. Delisting to OTC would materially reduce liquidity and institutional accessibility.
Historical shareholder litigation & investigations
Moderate
Multiple law firm investigations (Robbins 2021, Kessler Topaz, Glancy Prongay & Murray 2024) relating to prior Phase 2/3 data interpretation. No confirmed active class action from 2026, but historical governance record adds risk premium and constrains multiple.
Q1 2027 Phase 3 AD readout catalyst
Positive
Dated binary catalyst with defined statistical primary endpoint (ADAS-Cog13 change at 6 months). High-conviction positive result would trigger 300-500% re-rating and open partnership optionality. Rare in current market to have such a clean, dated catalyst.
Long-lived patent protection to 2047
Positive
Crystal form patent extension provides 20+ years of exclusivity if approved. Long IP runway supports higher NPV assumptions and makes the asset attractive to potential acquirers/partners.
No debt / clean balance sheet
Positive
Zero total debt — no covenant risk, no interest expense drag. Cash burn is the ONLY concern; company cannot go bankrupt from creditors, only run out of equity funding capacity. All liabilities are operating/trade payables.
article

SWOT analysis

Strengths
  • +Fully-enrolled 850-patient Phase 3 AD trial with DSMB safety clearance
  • +Q1 2027 primary readout is a defined, dated binary catalyst
  • +Zero debt — no default risk, only equity funding risk
  • +Patent protection to 2047 provides long commercial runway if approved
  • +Multi-target mechanism (amyloid + tau + α-synuclein) differentiates vs single-antigen agents
Weaknesses
  • −~5 months cash runway — forced raise imminent
  • −Nano-cap $54M with negative tangible book value
  • −Prior Phase 2/3 data controversy erodes management credibility
  • −Single-drug company — 100% dependent on buntanetap Phase 3
  • −Cumulative dilution: shares +330% over 2 years
Opportunities
  • →Positive Phase 3 primary readout unlocks +300-500% re-rating and partnership talks
  • →Parkinson's OLE data + PDD program add second/third value drivers
  • →Short squeeze potential (11.7% SI on 42.6M float) on positive print
  • →Alzheimer's market shifting toward disease-modifying agents ($30B+ TAM)
  • →Potential strategic partnership avoids full dilution scenario
Threats
  • !Phase 3 miss = −70% to −90% single-day drop, going-concern scenario
  • !Pre-readout raise at $0.75-1.00 dilutes existing holders 100%+
  • !NYSE delisting risk if price collapses below $1.00
  • !Competition from Leqembi/Kisunla (approved) and Anavex (also Phase 3)
  • !Trial execution delays could push readout beyond Q1 2027
article

Summary by assessment area

🔴 Financial & Dilution Risk — Critical
  • 5-month cash runway forcing near-term raise
  • Dilution 40-80M new shares expected
  • NYSE $1.00 minimum bid proximity
  • Negative tangible book value
🟡 Clinical & Execution Risk — High
  • Single-drug story; 100% dependence on Phase 3
  • CNS Phase 3 base rate 8-15% success
  • Historical data interpretation controversy
  • Vertex/Anavex competition in AD space
🟢 Catalyst & Optionality — Strong
  • Q1 2027 P3 primary readout (dated binary)
  • Q1 2028 disease-modifying secondary readout
  • PD OLE + PDD program add optionality
  • Patent to 2047 supports partnership value
Sources & Disclaimer

Sources: Annovis Bio investor relations (annovisbio.com press releases); SEC EDGAR 10-Q (Q2 2026 anvs-20260630x10q.htm, Q1 2026 anvs-20260331x10q.htm); StockAnalysis.com key statistics; Stocktwits real-time quote; StockTitan Q2 2026 earnings; GlobeNewswire Phase 3 full enrollment July 2026; Kessler Topaz historical case filings; Glancy Prongay & Murray 2024 investigation notice; Nasdaq/NYSE listing rules. Market data — last verified close 2026-09-22: ANVS ~$1.26 (one source primary; verify before positioning), market cap ~$54M, 52W range $1.04–$5.50, shares outstanding ~42.6M. Short interest ~11.7%. Cash $18.7M (Q2 2026), zero debt. Next earnings: est. Nov 14, 2026. This document is for informational purposes only and does not constitute financial or investment advice.